10-Q: Cardiff Lexington Corporation Reports Increased Revenue but Continues to Face Net Losses in Q1 2025

Cardiff Lexington Corporation's Q1 2025 shows revenue growth driven by its healthcare segment, but the company still reports a net loss and acknowledges material weaknesses in internal controls.

Summary

• Cardiff Lexington Corporation's Q1 2025 revenue increased by 25.56% to $2,915,567 compared to $2,322,132 in Q1 2024, driven by increased patient volume and more complex medical procedures in its healthcare segment.
• The company's cost of sales increased by 13.38% to $1,075,034, primarily due to higher laboratory fees and salaries, but decreased as a percentage of revenue from 40.83% to 36.87%.
• Gross profit increased by 33.96% to $1,840,533, with gross margin improving from 59.17% to 63.13%.
• Selling, general, and administrative expenses rose by 50.42% to $1,280,641, mainly due to increased salaries, bad debt expense, and billing costs.
• The company reported a net loss of $450,777, which is higher than the $283,104 loss in the same period last year.
• The company's net cash used in operating activities was $1,628,728, driven by the net loss and an increase in accounts receivable.
• The company is addressing material weaknesses in internal control over financial reporting through strategic hiring, training, documentation, and enhanced review processes.
• The company had $996,758 in cash as of March 31, 2025, and believes current working capital and additional financing will be sufficient to fund operations for at least a year.
• The company is seeking additional capital through equity and debt financings to fund acquisitions and operations.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue increased, the company still faces net losses and acknowledges material weaknesses in internal controls. The need for additional capital raises also adds uncertainty.

Positives

• Revenue increased by 25.56% due to higher patient volume and more complex medical procedures.
• Gross profit increased by 33.96%, and gross margin improved from 59.17% to 63.13%.
• The company is actively working to remediate material weaknesses in internal control over financial reporting.
• The company believes current working capital and additional financing will be sufficient to fund operations for at least a year.

Negatives

• The company reported a net loss of $450,777, which is higher than the $283,104 loss in the same period last year.
• Selling, general, and administrative expenses rose by 50.42% to $1,280,641.
• The company acknowledges material weaknesses in internal control over financial reporting.
• The company's net cash used in operating activities was $1,628,728.

Risks

• The company's ability to continue as a going concern is dependent on additional cash infusions.
• The company acknowledges material weaknesses in internal control over financial reporting, which could affect the reliability of financial reporting.
• The company is seeking additional capital through equity and debt financings, which may not be available on acceptable terms or at all.
• The company's high level of debt could restrict operations.
• The company's success depends on its ability to identify and acquire additional businesses, which may not be successful.

Future Outlook

The company believes that current working capital and additional financing should be sufficient to fund operations and satisfy obligations for at least one year. The company intends to raise capital for additional acquisitions primarily through equity and debt financings.

Management Comments

• Management has invested years working to develop a new and exciting housing development in Salmon, Idaho and plans to enter into a joint venture agreement with a developer for this planned concept development.
• We monitor outstanding cases as they develop through ongoing discussions with attorneys, doctors and our third-party medical billing company and additionally monitor our settlement realization rates over time.

Industry Context

The company operates primarily in the healthcare industry, specifically providing diagnostic and surgical services for injuries and disorders of the skeletal system. The company also has a real estate segment. The healthcare industry is subject to various regulations and trends, including changes in reimbursement rates, technological advancements, and increasing demand for healthcare services.

Comparison to Industry Standards

• It is difficult to compare Cardiff Lexington directly to industry standards due to its unique acquisition holding company model and focus on undervalued healthcare companies.
• However, the company's revenue growth in its healthcare segment can be compared to the growth rates of other medical service providers.
• The company's net loss and operating expenses can be compared to those of other small-cap healthcare companies.
• The company's reliance on debt financing and equity raises is common among small-cap companies in the healthcare sector.
• The company's real estate segment can be compared to other small real estate developers, but the company's plans to enter into a joint venture agreement make direct comparisons difficult.

Related Party Transactions

• In connection with the acquisition of Edge View on July 16, 2014, the Company assumed amounts due from previous owners who are current managers of Edge View.
• On August 25, 2023, the Company issued a twelve-month convertible promissory note in the principal amount of $5,000 to the Company's CEO for the Company's operating expenses.

Stakeholder Impact

• Shareholders may be concerned about the company's continued net losses and the need for additional capital raises.
• Employees may be affected by the company's efforts to remediate material weaknesses in internal control over financial reporting.
• Customers of the company's healthcare segment may benefit from the company's increased revenue and ability to provide more complex medical procedures.
• Creditors may be affected by the company's reliance on debt financing.

Next Steps

• The company intends to continue implementing remedial procedures to address material weaknesses in internal control over financial reporting.
• The company intends to raise capital for additional acquisitions primarily through equity and debt financings.
• The company plans to enter into a joint venture agreement with a developer for its planned concept development in Salmon, Idaho.

Key Dates

Keywords

financial results, healthcare, revenue, net loss, acquisitions, Cardiff Lexington, internal controls, operating expenses